Key Takeaways:
Grace Therapeutics Inc. (Nasdaq: GRCE) received a Complete Response Letter from the U.S. Food and Drug Administration for its brain hemorrhage drug GTx-104, citing three areas of deficiency and halting the drug’s path to market.
"We are confident in the robust data package supporting our NDA submission, and that the CMC issues identified by the FDA can be successfully addressed in our resubmission,” Prashant Kohli, Chief Executive Officer of Grace Therapeutics, said in a statement.
The FDA’s rejection letter highlighted outstanding items related to Chemistry, Manufacturing, and Controls (CMC), including leachables data for product packaging and manufacturing deficiencies at a contract manufacturer. The agency also cited a need for non-clinical product toxicology risk assessments but did not request additional clinical data.
The decision is a significant setback for what could have been the first new treatment for aneurysmal subarachnoid hemorrhage (aSAH) in more than 40 years, a condition affecting an estimated 42,500 U.S. hospital patients annually. The company will request a Type A meeting with the FDA to clarify a path forward.
The rejection comes amid a tougher regulatory environment at the FDA, which has recently denied approvals for drugs from companies like Replimune Group and Disc Medicine. The agency has also increased its transparency by publishing redacted CRLs, a move that has drawn criticism from some corners of the pharmaceutical industry for creating potential competitive harm and public confusion, according to a recent citizen petition.
Grace Therapeutics' application was supported by the STRIVE-ON trial, which compared GTx-104 to oral nimodipine. The trial met its primary endpoint, with patients on GTx-104 showing a 19% reduction in episodes of clinically significant hypotension compared to the oral version (28% versus 35%).
Data also showed that 54% of patients on GTx-104 maintained a relative dose intensity of 95% or higher, compared to only 8% for oral nimodipine, suggesting more consistent drug exposure. However, there were eight deaths in the GTx-104 arm compared to four in the oral nimodipine arm, though none were determined to be related to the drug itself.
GTx-104 is a novel, injectable formulation of nimodipine designed for intravenous infusion. It aims to provide more consistent delivery and avoid issues common with oral administration in unconscious or dysphagic aSAH patients.
The CRL for Grace Therapeutics extends a period of uncertainty for drug developers facing a more stringent FDA. The rejection puts the stock at risk of a significant decline as investors recalibrate expectations for GTx-104's approval timeline. Grace Therapeutics' next catalyst will be the outcome of its planned Type A meeting with the FDA.
This article is for informational purposes only and does not constitute investment advice.
